Biotech

The biotechnology sector, encompassing innovative drug development, biologics, and advanced therapies, stands as a cornerstone of modern healthcare with a global TAM exceeding $2 trillion in 2026 and projected to surpass $4-9 trillion by 2035 at a robust 13-14% CAGR. Key growth drivers include breakthroughs in GLP-1 agonists for metabolic diseases, oncology immunotherapies, gene editing (CRISPR), and precision medicine fueled by aging populations, rising chronic disease prevalence, and AI-accelerated R&D. The central investment tension revolves around balancing extraordinary pipeline innovation and blockbuster potential against high clinical trial failure rates, regulatory hurdles, patent cliffs, and intense pricing pressures from payers and governments.

• Companies primarily engaged in discovery, development, and commercialization of biologic drugs, vaccines, gene therapies, and advanced modalities
• Firms leveraging biotechnology platforms such as monoclonal antibodies, cell/gene therapy, RNA technologies, and recombinant proteins
• Integrated pharmaceutical companies with significant biotech R&D and biologics portfolios
• Diagnostics and tools companies using biotech methods for molecular testing and companion diagnostics
• Animal health and agricultural biotech leaders applying similar scientific platforms

• Pure medical device manufacturers without biotech components
• Healthcare providers, insurers, pharmacies, and service-oriented companies
• Traditional small-molecule chemical drug firms lacking meaningful biotech platforms

• Revenue TTM
• YoY Revenue Growth
• Op. Margin
• Net Margin
• R&D Intensity
• Revenue Trend

5

3

5

5

3

4

1

5

1

1

1

1

4

4

3

4

3

4

1

1

1

1

2

2

4

2

3

3

5

3

2

3

5

5

2

3

2

2

2

2

1

3

4

3

2

2

3

3

3

5

4

3

4

5

4

5

5

5

4

4

3

2

4

3

4

4